Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia

• Published in: Blood Vol. 128; no. 10; pp. 1382 - 1395
• Main Authors: Khaw, Seong Lin, Suryani, Santi, Evans, Kathryn, Richmond, Jennifer, Robbins, Alissa, Kurmasheva, Raushan T., Billups, Catherine A., Erickson, Stephen W., Guo, Yuelong, Houghton, Peter J., Smith, Malcolm A., Carol, Hernan, Roberts, Andrew W., Huang, David C.S., Lock, Richard B.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 08.09.2016; American Society of Hematology
• Subjects: Animals; Antineoplastic Agents - therapeutic use; Apoptosis - drug effects; Apoptosis - genetics; Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic - therapeutic use; Cell Proliferation - drug effects; Child; Drug Resistance, Neoplasm - drug effects; Drug Resistance, Neoplasm - genetics; Female; Flow Cytometry; Gene Rearrangement - genetics; Histone-Lysine N-Methyltransferase - genetics; Humans; Lymphoid Neoplasia; Mice; Mice, Inbred NOD; Mice, SCID; Myeloid-Lymphoid Leukemia Protein - genetics; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics; Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - genetics; Sulfonamides - therapeutic use; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

The clinical success of the BCL-2-selective BH3-mimetic venetoclax in patients with poor prognosis chronic lymphocytic leukemia (CLL) highlights the potential of targeting the BCL-2-regulated apoptotic pathway in previously untreatable lymphoid malignancies. By selectively inhibiting BCL-2, venetocl...